Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lineage Cell Therapeutics Inc. Director's Dealing 2012

Jul 3, 2012

6895_dirs_2012-07-03_476ef0c0-1f1b-4aa8-9116-2d77ad00788b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2012-07-01

Reporting Person: LICHTINGER PEDRO (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-07-01 Option to Purchase Common Shares $4.60 A 20000 Acquired 2017-06-30 Common Shares (20000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Shares, no par value 6250 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Option to Purchase Common Shares $5.13 2016-06-30 Common Shares (20000) 20000 Direct
Option to Purchase Common Shares $5.45 2015-08-09 Common Shares (20000) 20000 Direct
Option to Purchase Common Shares $3.45 2014-08-10 Common Shares (20000) 20000 Direct

Footnotes

F1: Does not include shares that may be acquired upon the exercise of certain stock options.

F2: 5,000 options will become exercisable on September 30, 2012; December 31, 2012; March 31, 2013; and June 30, 2013 based upon continued service on the board of directors.

F3: 5,000 options became exercisable on September 30, 2011; December 31, 2011; March 31, 2012; and June 30, 2012.

F4: 5,000 options became exercisable on September 30, 2010; December 31, 2010; March 31, 2011; and June 30, 2011.

F5: 5,000 options became exercisable on September 30, 2009; December 31, 2009; March 31, 2010; and June 30, 2010.